TALENT—neoadj TDXd (6-8 cycles) +/- AI in HER2 low HR+ early stage breast ca

Stephanie Graff, MD, FACP, FASCO· @DrSGraff · X·2026-10-23 19:45· 2 天前评分90

正文 · 原文

TALENT—neoadj TDXd (6-8 cycles) +/- AI in HER2 low HR+ early stage breast ca
ypCR // RCB
TDXd 7% // 16%
T-DXd/AI: 3% // 9%
T-DXd→ TC: 17% // 17%

Author concludes “modest” benefit; I would say “disappointing”. ypCR just isn’t the same endpoint w/ ER+ disease #ESMO26 @OncoAlert

564 浏览 · 17 赞 · 8 转发 · 0 回复

会议摘要

LBA23按 Proffered paper 1: Breast cancer, early and advanced stage 对上

Final results of TALENT: A neoadjuvant trial of T-DXd with or without anastrozole, or in sequence with chemotherapy for HER2-low, HR+ early-stage breast cancer

https://esmocongress.esmo.org

来源：Stephanie Graff, MD, FACP, FASCO · x.com